Related content

Phase I/II study of treatment with matured dendritic cells with or without low dose IL-2 in patients with disseminated melanoma

By Hersey P.   Halliday G.   Farrelly M.   DeSilva C.   Lett M.   Menzies S.  

Cancer Immunology, Immunotherapy, Vol. 57, Iss. 7, 2008-07 ,pp. : 1039-1051

Springer Publishing Company

Access to resources Recommend Favorite

Autologous Dendritic Cell Based Adoptive Immunotherapy of Patients with Colorectal Cancer—A Phase I-II Study

By Hunyadi János   András Csilla   Szabó Imre   Szántó János   Szluha Kornélia   Sipka Sándor   Kovács Péter   Kiss Attila   Szegedi Gyula   Altorjay István   Sápy Péter   Antal-Szalmás Péter   Tóth László   Fazekas György   Rajnavölgyi Éva  

Pathology & Oncology Research, Vol. 20, Iss. 2, 2014-04 ,pp. : 357-365

Springer Publishing Company

Access to resources Recommend Favorite

Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma

By                      

International Journal of Oncology, Vol. 41, Iss. 5, 2012-01 ,pp. : 1601-1609

Spandidos Publications

Access to resources Recommend Favorite

Dendritic cell-based vaccination in metastatic melanoma patients: Phase II clinical trial

By                            

Oncology Reports, Vol. 28, Iss. 4, 2012-01 ,pp. : 1131-1138

Spandidos Publications

Access to resources Recommend Favorite

Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell line lysate

By Vilella R.   Benítez D.   Milà J.   Lozano M.   Vilana R.   Pomes J.   Tomas X.   Costa J.   Vilalta A.   Malvehy J.   Puig S.   Mellado B.   Martí R.   Castel T.  

Cancer Immunology, Immunotherapy, Vol. 53, Iss. 7, 2004-07 ,pp. : 651-658

Springer Publishing Company

Access to resources Recommend Favorite